Peptide safety, stated plainly
The risks that apply to nearly every compound in this library, regardless of what it claims to do.
If you are having a medical emergency, stop reading and call your local emergency number. Chest pain, difficulty breathing, a severe allergic reaction, a prolonged erection lasting over four hours, or signs of infection at an injection site all need immediate care, not a web page.
1. Most of these are not approved medicines
Of the 73 compounds in this library, 25 are FDA-approved for at least one indication. The rest are approved only elsewhere, still in trials, or sold under "research use only" labelling. That label is a legal device, not a safety statement — it means the seller is not claiming it is fit for human use, which is precisely the problem.
2. Product quality is a genuine, documented hazard
Independent testing of grey-market peptide vials has repeatedly found products that are underdosed, overdosed, degraded, contaminated with bacteria or endotoxin, or simply a different compound than the label claims. A certificate of analysis supplied by the seller is not independent verification. This risk is separate from, and additional to, whatever the peptide itself might do.
3. Sterility and injection technique
Most of these compounds are injected, often reconstituted at home from lyophilised powder. Abscesses, cellulitis and bloodstream infections are recurring consequences of non-sterile technique. Reusing needles, reconstituting with non-sterile water, and storing reconstituted peptide improperly all cause real harm — the compound need not be pharmacologically dangerous for the practice to be.
4. Growth signalling and cancer
A large fraction of popular peptides work by promoting growth, blood vessel formation, cell survival or telomerase activity. Those are also the mechanisms tumours exploit. This does not mean any given peptide causes cancer — it means the question has not been studied in humans for most of them, and anyone with a cancer history or an undiagnosed lump should treat that gap as disqualifying rather than reassuring.
5. Immune modulation is not inherently good
"Immune support" peptides shift immune function rather than simply improving it. Stimulating T-cell activity is contraindicated in autoimmune disease and after transplant. Suppressing inflammatory signalling has implications for infection control and tumour surveillance. Direction matters more than intensity.
6. Interactions and existing conditions
Growth hormone secretagogues worsen insulin resistance and matter enormously if you are diabetic. Melanocortin agonists raise blood pressure. GLP-1 agonists change how fast your stomach empties, which affects both other oral medications and anesthesia safety. Nothing in this library is inert.
7. If you compete in tested sport
Most peptides in this library are on the WADA prohibited list, including BPC-157, TB-500, all growth hormone secretagogues and IGF-1 analogs. Athletes have been sanctioned for compounds marketed as harmless recovery aids.
8. What actually reduces risk
- Tell your doctor. Including if you expect disapproval — anesthesiologists and surgeons in particular need to know.
- Prefer approved drugs through pharmacies. If an approved option exists for your goal, the risk arithmetic is not close.
- Get baseline bloodwork. Metabolic panel, HbA1c, IGF-1 and a lipid panel give you something to compare against.
- Change one thing at a time. Stacking multiple compounds makes it impossible to attribute either benefit or harm.
- Know your stop conditions in advance. Decide what would make you stop before you start, not while symptomatic.
- Do not treat a serious condition with an unapproved peptide. The opportunity cost of delaying effective treatment is often the largest risk of all.
Our position We publish this because people are going to research these compounds either way, and the alternative sources are selling them. Documenting risks accurately is harm reduction — it is not encouragement, and this page is not a protocol.